AnaptysBio's Q1 collaboration revenue falls, net loss widens

AnaptysBio

12/05/2026 21:26

Overview

Biotech royalty manager's Q1 collaboration revenue declined yr/yr as Vanda license revenue fell

Net loss widened in Q1 from prior year, reflecting higher G&A expenses and spin-off costs

Company announced $100 mln stock repurchase plan expiring Dec. 31, 2026

Outlook

AnaptysBio expects to achieve >$390 mln in annualized Jemperli royalties as early as 2029

Company anticipates paydown of remaining ~$325 mln non-recourse debt monetization by end of Q2 2027

FDA target action date for imsidolimab in GPP is Dec. 12, 2026

Result Drivers

JEMPERLI ROYALTY GROWTH - Co said Jemperli royalties rose 44% yr/yr, partially offsetting lower Vanda license revenue

VANDA LICENSE REVENUE DECLINE - Co attributed lower collaboration revenue mainly to a decrease in Vanda license revenue

HIGHER G&A COSTS - Co said general and administrative expenses rose due to legal costs for the separation, ongoing GSK litigation, and higher non-cash stock compensation

Company press release: ID:nGNX81VlF9

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Collaboration Revenue
$25.56 mln
Q1 Net Income
-$52.88 mln
Q1 Income From Operations
-$34.64 mln
Q1 Operating Expenses
$60.19 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for AnaptysBio Inc is $79.50, about 17% above its May 11 closing price of $67.92

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)